cGAS-STING Pathway and EBC-46: How Cytosolic DNA Sensing Links Cell Death to Antitumour Immunity

The cGAS-STING pathway is one of the most actively investigated innate-immune signalling axes in cancer biology. It sits at the intersection of DNA damage, cell death, and type I interferon (IFN) response — exactly the territory that tigilanol tiglate occupies when it triggers vascular collapse and tumour-cell necrosis in preclinical and clinical settings. This article walks through how cGAS-STING works, why it is relevant to the EBC-46 literature, and where the gaps in evidence sit.

The Sensor and the Adaptor

Cyclic GMP-AMP synthase (cGAS) is a cytosolic enzyme that binds double-stranded DNA in a sequence-independent manner. When DNA appears in the cytoplasm — where it should not be — cGAS dimerises and synthesises 2',3'-cyclic GMP-AMP (cGAMP), a second messenger. cGAMP then binds the endoplasmic-reticulum-resident adaptor protein STING (stimulator of interferon genes), which oligomerises and translocates to the Golgi.

From the Golgi, STING recruits TBK1 (TANK-binding kinase 1), which phosphorylates the transcription factor IRF3. Phosphorylated IRF3 dimerises and translocates to the nucleus, driving transcription of type I interferons (IFN-α and IFN-β) and IFN-stimulated genes. The downstream effect is two-fold: an autocrine antiviral state in the cell that detected the cytosolic DNA, and a paracrine signal that recruits and activates dendritic cells, NK cells, and CD8+ T cells.

Why Cytosolic DNA Appears After Tumour Cell Death

Healthy cells keep their genomic DNA inside the nucleus and their mitochondrial DNA inside mitochondria. Several events break this compartmentalisation: micronuclei from missegregated chromosomes, mitochondrial outer membrane permeabilisation during apoptosis, and frank membrane disruption during necrotic and necroptotic cell death. Each of these releases DNA into the cytoplasm where cGAS can detect it.

Tigilanol tiglate produces rapid, large-volume tumour-cell necrosis through PKC-dependent vascular disruption and direct membrane effects. This profile — extensive necrotic cell death within hours of administration — is the kind of event that would be expected to release large quantities of tumour DNA into the local extracellular environment, where it can then be taken up by neighbouring viable cells or by infiltrating phagocytes that subsequently re-export it into their own cytosol. See our recent piece on pyroptosis as an additional cell-death route for tigilanol tiglate for related mechanism discussion.

cGAS-STING as a Bridge to Adaptive Immunity

The clinically interesting feature of cGAS-STING activation is that it bridges innate sensing to adaptive antitumour T-cell responses. Dendritic cells that take up tumour DNA and activate STING produce type I IFNs and undergo maturation; they then cross-present tumour antigens to CD8+ T cells in draining lymph nodes. This is the cellular mechanism behind the "abscopal effect" observed when localised therapies (radiation, intratumoural injection) produce systemic immune responses against untreated tumours elsewhere in the body.

A 2017 study published in Nature Communications demonstrated that STING activation in the tumour microenvironment is necessary for spontaneous antitumour CD8+ T-cell responses. More recent work has extended this to oncolytic agents and intratumoural therapies, showing that the magnitude of STING-dependent type I IFN signalling correlates with the strength of subsequent adaptive immune responses.

What the EBC-46 Literature Does and Does Not Show

Direct studies of cGAS-STING activation by tigilanol tiglate are limited. Published preclinical and veterinary studies focus on the proximate cytotoxic and vascular-disruption mechanisms — PKC activation, endothelial collapse, neutrophil-driven inflammation — rather than on type I IFN signalling per se. However, several indirect lines of evidence are consistent with cGAS-STING involvement: tumour regression at sites distant from the injection in some veterinary cases (suggestive of systemic immune engagement), neutrophil and CD8+ T-cell infiltration on histology, and persistent local immune memory at re-challenge.

It is fair to describe cGAS-STING as a plausible secondary mechanism that has not been definitively proven in the tigilanol tiglate context. Confirming it would require IFN-β reporter assays, STING-knockout tumour models, and cGAS-deficient mouse studies — none of which appear in the public literature for tigilanol tiglate as of 2026.

Important Distinction: Pharmaceutical vs. Supplement

All cell-death and immune-activation studies discussed above used pharmaceutical-grade tigilanol tiglate (the QBiotics injectable currently approved as Stelfonta for canine mast cell tumours), not oral blushwood berry extract supplements. Oral dietary supplements such as those produced by Blushwood Health contain the whole-seed blushwood berry extract rather than isolated tigilanol tiglate, and they enter the body through a different route. None of the mechanistic studies covered in this article can be directly translated to oral supplement use. Blushwood Health products are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease.

Open Questions

Three research questions sit at the frontier of cGAS-STING and tigilanol tiglate. First: does intratumoural tigilanol tiglate produce a measurable IRF3 activation signature in tumour-infiltrating dendritic cells? Second: is the abscopal-like effect observed in some veterinary cases dependent on STING in host cells? Third: does combining tigilanol tiglate with checkpoint inhibitors (anti-PD-1, anti-CTLA-4) produce additive or synergistic responses, as predicted if both agents engage the cGAS-STING-IFN axis? Each of these questions is testable and is likely to be addressed as the clinical program advances.

Citations

1. Ablasser A et al., Nature, 2013 — cGAS produces cGAMP.

2. Marcus A et al., Nature Communications, 2017 — STING in tumour immunity.

3. US FDA — Stelfonta approval (canine mast cell tumours), 2020.

4. QBiotics Group — Tigilanol Tiglate program, 2026.

Related Articles

Continue with related mechanism pieces: pattern recognition receptors, pyroptosis and gasdermins, or our complete EBC-46 mechanism overview.